These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 29127628

  • 21. VE1 immunohistochemistry is an adjunct tool for detection of BRAFV600E mutation: Validation in thyroid cancer patients.
    Rashid FA, Tabassum S, Khan MS, Ansari HR, Asif M, Sheikh AK, Sameer Aga S.
    J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405
    [Abstract] [Full Text] [Related]

  • 22. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: Comparative analysis of two VE1 antibodies.
    Oh KY, Cho SD, Yoon HJ, Lee JI, Hong SD.
    J Oral Pathol Med; 2021 Jan; 50(1):85-91. PubMed ID: 32939809
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.
    Ida CM, Vrana JA, Rodriguez FJ, Jentoft ME, Caron AA, Jenkins SM, Giannini C.
    Acta Neuropathol Commun; 2013 May 30; 1():20. PubMed ID: 24252190
    [Abstract] [Full Text] [Related]

  • 25. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
    Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP.
    Hum Pathol; 2013 Nov 30; 44(11):2563-70. PubMed ID: 24071017
    [Abstract] [Full Text] [Related]

  • 26. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, Zhou X.
    Exp Mol Pathol; 2016 Feb 30; 100(1):236-41. PubMed ID: 26795218
    [Abstract] [Full Text] [Related]

  • 27. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rössle M.
    Cancer Cytopathol; 2014 Jan 30; 122(1):48-58. PubMed ID: 24039206
    [Abstract] [Full Text] [Related]

  • 28. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.
    Na JI, Kim JH, Kim HJ, Kim HK, Moon KS, Lee JS, Lee JH, Lee KH, Park JT.
    Virchows Arch; 2015 Aug 30; 467(2):155-68. PubMed ID: 25894433
    [Abstract] [Full Text] [Related]

  • 29. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
    Kleinschmidt-DeMasters BK, Aisner DL, Foreman NK.
    Am J Surg Pathol; 2015 Apr 30; 39(4):528-40. PubMed ID: 25581727
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, von Knebel Doeberitz M, Kloor M.
    Int J Cancer; 2013 Oct 01; 133(7):1624-30. PubMed ID: 23553055
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.
    Schafroth C, Galván JA, Centeno I, Koelzer VH, Dawson HE, Sokol L, Rieger G, Berger MD, Hädrich M, Rosenberg R, Nitsche U, Schnüriger B, Langer R, Inderbitzin D, Lugli A, Zlobec I.
    Oncotarget; 2015 Dec 08; 6(39):41453-63. PubMed ID: 26496026
    [Abstract] [Full Text] [Related]

  • 35. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
    Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N.
    BMC Cancer; 2015 May 01; 15():340. PubMed ID: 25929517
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay.
    Qiu T, Lu H, Guo L, Huang W, Ling Y, Shan L, Li W, Ying J, Lv N.
    Sci Rep; 2015 Mar 18; 5():9211. PubMed ID: 25784606
    [Abstract] [Full Text] [Related]

  • 38. VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex without detectable BRAF V600E mutations.
    Mordes DA, Lynch K, Campbell S, Dias-Santagata D, Nose V, Louis DN, Hoang MP.
    Am J Clin Pathol; 2014 Jun 18; 141(6):811-5. PubMed ID: 24838325
    [Abstract] [Full Text] [Related]

  • 39. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
    Huang WK, Kuo TT, Wu CE, Cheng HY, Hsieh CH, Hsieh JJ, Shen YC, Hou MM, Hsu T, Chang JW.
    Asia Pac J Clin Oncol; 2016 Dec 18; 12(4):403-408. PubMed ID: 27488807
    [Abstract] [Full Text] [Related]

  • 40. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
    Anwar MA, Murad F, Dawson E, Abd Elmageed ZY, Tsumagari K, Kandil E.
    J Surg Res; 2016 Jun 15; 203(2):407-15. PubMed ID: 27363650
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.